Reply: RE: A Cost-Effectiveness Modeling Evaluation Comparing a Biosimilar Follitropin Alfa Preparation With Its Reference Product for Live Birth Outcome in Germany, Italy and Spain

Journal of Medical Economics - United Kingdom
doi 10.1080/13696998.2019.1576182
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Informa UK Limited

Related search

RE: A Cost-Effectiveness Modeling Evaluation Comparing a Biosimilar Follitropin Alfa Preparation With Its Reference Product for Live Birth Outcome in Germany, Italy and Spain

Journal of Medical Economics
Health Policy
2019English

Pmu40 - Live Birth Rate (Lbr), Ongoing Pregnancy Rate (Opr) and Ovarian Hyperstimulation Syndrome (Ohss) Risk With Originator Versus Biosimilar Recombinant Follitropin Alfa: A Pooled Analysis of Clinical Trial Data

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Glycosylation Pattern and in Vitro Bioactivity of Reference Follitropin Alfa and Biosimilars

Frontiers in Endocrinology
EndocrinologyMetabolismDiabetes
2019English

A Prospective Follow-Up on Neonatal Health Following Controlled Ovarian Stimulation With Follitropin Delta or Follitropin Alfa

Fertility and Sterility
GynecologyReproductive MedicineObstetrics
2018English

Authors' Reply Re: Medical Therapy for Preventing Recurrent Endometriosis After Conservative Surgery: A Cost-Effectiveness Analysis

BJOG: An International Journal of Obstetrics and Gynaecology
GynecologyObstetrics
2018English

Authors' Reply Re: Cost-Effectiveness of a Pro-Active Approach of Urinary Incontinence in Women

BJOG: An International Journal of Obstetrics and Gynaecology
GynecologyObstetrics
2016English

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

2017English

The Air-Abrasive Technique: A Re-Evaluation of Its Use in Fossil Preparation

Palaeontologia Electronica
Oceanography
2018English

Psy95 - Exploring the Potential Cost-Effectiveness of Emicizumab for Hemophilia a With Inhibitor in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy